Explore the latest developments concerning Triple-action drug retatrutide.
Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds
This article has been reviewed according to Science X's
editorial process
and policies.
Editors have highlighted
the following attributes while ensuring the content's credibility:
A recent Phase III clinical trial, TRIUMPH-2, evaluated the efficacy and safety of retatrutide, a triple receptor agonist and experimental once-weekly injection being developed to treat obesity and type 2 diabetes. What sets it apart from drugs such as semaglutide (Wegovy), which targets one hormone, and tirzepatide (Zepbound), which targets two, is its ability to activate three hormone receptors at once.
Developed by Eli Lilly, retatrutide mimics GLP-1, which lowers blood sugar and promotes fullness, and GIP, which enhances the body's insulin response and helps reduce body weight alongside GLP-1. It also activates glucagon receptors, adding a third mechanism that increases energy expenditure and metabolic activity, helping the body burn more energy.
PowMr MPPT 45A 35A 25A Solar Charger Controller 12V 24V Auto Lifepo4 Battery Charger Solar Panel Regulator Max PV Input 100VDC
Beyond Ozempic? New Weight Loss Drug Shows Stunning Results in Major Clinical Trial
Retatrutide could help tackle obesity and type 2 diabetes together, with an 80-week trial showing substantial weight loss and better blood sugar control alongside more nausea and diarrhea.
A weekly injection beneath the skin helped adults with excess weight and type 2 diabetes lose nearly a fifth of their starting weight, on average, at the highest dose tested. That is a substantial shift on the scale for a population that has generally lost less weight with obesity medications than people without diabetes.
Researchers tested the investigational drug retatrutide over 80 weeks in TRIUMPH-2, a completed phase 3 trial involving 1,152 adults with overweight or obesity and type 2 diabetes. Participants received weekly injections of the drug or a placebo, alongside dietary counseling and guidance on physical activity. Eli Lilly, which manufactures retatrutide, sponsored the study, and the findings were published in The Lancet.
For more detailed information, explore updates concerning Triple-action drug retatrutide.